Subscribe
Close
  • Free for qualified executives and consultants to industry

  • Receive quarterly issues of Area Development Magazine and special market report and directory issues

Renew

Marker Therapeutics Relocates Headquarters to Houston, Texas

02/19/2019
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, relocated its corporate headquarters from Jacksonville, Florida to Houston, Texas.

The Company also announced that it is now a resident company at Johnson & Johnson Innovation, JLABS, an incubator located in the heart of the Texas Medical Center, to access a fully equipped laboratory to conduct research and development.

"Our new headquarters will enable us to leverage our strategic partnership with Baylor College of Medicine and proximity to one of the largest and most vibrant communities of cell therapy professionals in the United States," commented Peter L. Hoang, President & CEO of Marker Therapeutics.

Mr. Hoang continued, "The Houston region is home to many companies and research institutions in the biotech and pharmaceutical industry, particularly within the growing field of cell therapy. The area offers Marker Therapeutics a professional, well-educated workforce that will allow us to recruit top scientific, clinical, manufacturing, and commercial talent with pharmaceutical industry experience. Access to these resources will be critical as we build our capabilities from research through clinical, regulatory, and CMC development to advance and accelerate our product development. We are confident that Houston will offer Marker Therapeutics and our employees an excellent quality of life and a positive business climate,” he added.

The Company previously entered into a 38-month lease for 5,310 square feet in the Phoenix Tower in Houston. The new headquarters will house certain members of the Company's corporate and administrative staff and with the new laboratory facility, allow the Company to conduct research and development in Houston. Although the Company will be headquartered in Houston, certain personnel will continue to operate in proximity to major academic and clinical partners in the Jacksonville location.

In addition to its new corporate headquarters, the Company also entered into an agreement with Johnson & Johnson Innovation, JLABS for the use of a dedicated portion of an existing laboratory located at the Texas Medical Center in Houston for the purpose of conducting laboratory research and other laboratory related activities. JLABS at TMC, established by Johnson & Johnson Innovation, provides research and development stage entities with access to a turnkey infrastructure that includes singular benchtops, modular wet lab units, office space and specialized laboratory equipment.

"Our new laboratory facility in Houston provide us with the capability to accelerate and augment the scientific and clinical development of our therapies in close cooperation with our partners at Baylor College of Medicine," commented Dr. Juan F. Vera, Chief Development Officer of Marker Therapeutics. "JLABS at TMC delivers reduced infrastructure costs and centralized management of shared facilities that will allow us to efficiently use our resources toward building value for our shareholders through innovation."

Share

Exclusive Research